{"id":568869,"date":"2021-10-13T16:12:01","date_gmt":"2021-10-13T16:12:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=568869"},"modified":"2021-10-13T16:12:01","modified_gmt":"2021-10-13T16:12:01","slug":"graftversushost-disease-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/graftversushost-disease-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments_568869.html","title":{"rendered":"Graft-versus-host disease Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments"},"content":{"rendered":"
\n
\"Graft-versus-host<\/a><\/div>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
“Graft versus host disease (GVHD) Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Graft versus host disease (GVHD) market. A detailed picture of the Graft versus host disease (GVHD) pipeline landscape is provided, which includes the disease overview and Graft versus host disease (GVHD) treatment guidelines.<\/div>\n

DelveInsight’s “Graft-versus-host disease Pipeline Insight”<\/a><\/strong> report provides comprehensive insights about key companies and pipeline drugs in the Graft-versus-host disease pipeline landscapes. <\/p>\n

The report comprises Graft-versus-host disease pipeline<\/strong> drug profiles, including clinical and non-clinical stage products. It also includes the Graft-versus-host disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Graft-versus-host disease pipeline products.     <\/p>\n

\"\"<\/p>\n

Graft-versus-host disease Overview<\/strong><\/p>\n

Graft-versus-host disease (GvHD) is an immune condition that occurs when immune cells (T cells) after transplant procedures from the donor (known as the graft or graft cells) attack the recipient patient host’s tissues (healthy cells); the disease is a side effect that is common after an allogeneic bone marrow transplant (stem Cell Transplantation).<\/p>\n

Some of the key takeaways from the Graft-versus-host disease Pipeline Report:<\/a><\/strong><\/p>\n